secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0000950170-24-088581
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion Q2 net loss $37.3M; FDA clinical hold on diabetes trials; topline readouts on track for Q4
--------------------------------------------------------------------------------

- Net loss $37.3M in Q2 vs $24.9M YoY; cash $113.7M, down from $177.2M end of 2023.
- FDA imposed full clinical hold on BMF-219 diabetes trials due to hepatotoxicity concerns.
- Topline data from Phase 2b (type 2, ~195 pts) and Phase 2a (type 1, ~20 pts) still expected Q4 2024.
- Third obesity program (oral GLP-1R agonist) to be announced Q3 2024.
- Two COVALENT-101 cohorts (CLL, DLBCL) discontinued due to insufficient enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017024088581/0000950170-24-088581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017024088581/bmea-20240731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer